Amgen Inc. (NASDAQ:AMGN – Free Report) – Investment analysts at William Blair reduced their FY2025 ... and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women ...
William Blair downgraded Sprinklr (CXM) to Market Perform from Outperform without a price target after the company announced a 15% global workforce reduction. While expectations are low for the ...
The genetic landscape and biomarker datasets were compared to test whether there was a cumulative effect of rare genetic variants on the inflammatory disease signature. Results: We found a strong ...
In here, we explore the therapeutic landscape for rare diseases, analyzing drugs in development and those already approved by the European Medicines Agency (EMA). We differentiate between orphan drugs ...
تعد وكالة الأنباء السعودية التي تأسست في عام 1971م، المصدر الأول لتغطية الأخبار والفعاليات المحلية التي تهم المواطن والمقيم، وتقدم محتوى ...
The onset of the Covid-19 pandemic five years ago underscored the importance of diagnostic and vaccine developers to treat and prevent infectious diseases. Infectious disease is a theme for the ...
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a Outperform recommendation. As of January 29, 2025, the average one-year ...
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback